Vivimed Labs Q2FY18 consolidated net profit declines 17.8% yoy

India Infoline Research Team | November 14, 2017 19:37 IST

Vivimed Labs Ltd Q2FY18

Consolidated Results Q2FY18: (Rs. in crore)

Q2FY18 YoY (%)
Revenue 282.5 [6.6]
EBITDA 62.59 [2.7]
EBITDA Margin (%) 22.2 89
Net Profit (adjusted) 22 [17.8]
***EBITDA margin change is bps

Vivimed Labs consolidated revenue for the quarter came in at Rs. 282.5 crore, registering 6.6% yoy decline. This was primarily driven by 37% yoy decline in revenue from speciality chemical business.

EBITDA for the quarter fell by 2.7% yoy to Rs. 62.59 crore with a corresponding margin expansion of 89 bps. EBITDA margin for the quarter stood at 22.2%. This margin expansion was aided by 20% yoy decline in cost of materials.

The PAT for the quarter came in at Rs. 22 crore, yoy decline of 17.8%. This was due to 43% yoy rise in interest income.



Technical View:

Vivimed Labs Ltd ended at Rs. 117.10, down by 0.25 points or 0.21% from its previous closing of Rs. 117.35 on the BSE.
The scrip opened at Rs. 117.75 and touched a high and low of Rs. 121.95 and Rs. 116.75 respectively. A total of 7,92,394(NSE+BSE) shares were traded on the counter. The stock traded above its 50 DMA.

BSE 116.95 [3.15] ([2.62]%)
NSE 116.80 [3.10] ([2.59]%)

***Note: This is a NSE Chart

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.